TP53 and myelodysplastic syndrome: MDS patients with TP53 mutations represent a distinct molecular cohort with uniformly poor prognosis, however, the TP53 mutation status remained the most important additional risk factor not considered by the currently existing prognostic scoring systems [9,10,11,55,56].